We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
Read MoreHide Full Article
Key Takeaways
MindMed is enrolling two phase III GAD studies with top-line data due in 2026.
MNMD's phase III Emerge study in MDD enrolled faster, with top-line data now expected in mid-2026.
MindMed shares rose 101.2% in six months. A $258.9M financing strengthens its balance sheet.
Mind Medicine (MindMed) (MNMD - Free Report) is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Two pivotal phase III studies — Voyage and Panorama — are currently enrolling MM120 ODT in GAD, a debilitating mental health condition where there is an urgent need for transformational innovation, with the last new drug approval occurring in 2007. Earlier data from the phase II study on MM120 ODT demonstrated efficacy that far exceeded the current standard of care and a favorable tolerability profile.
Top-line data from the Voyage study is anticipated in the first half of 2026, while that from Panorama is expected in the second half of 2026.
A phase III study called Emerge of MM120 ODT in MDD has enrolled faster than expected, with top-line data now expected in mid-2026, earlier than the prior expectation of the second half of 2026. The company plans to initiate Ascend, its second phase III study in MDD, in mid-2026.
MindMed’s rapid pipeline progress in 2025 led the stock to rise 101.2% in the past six months, outperforming the industry’s increase of 27.6%.
Image Source: Zacks Investment Research
MindMed’s second asset in the pipeline, MM402, is being developed for autism spectrum disorder. A phase II study is expected to be initiated by the end of 2025.
With three pivotal data readouts expected, 2026 could be transformational for MindMed. Its recent $258.9 million financing has further strengthened its balance sheet, which should allow it to accelerate the development of MM120.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2025 adjusted EPS have increased from $7.29 to $7.56. Over the same period, EPS estimates for 2026 have surged from $7.81 to $8.08. Shares of ANIP have surged 52.1% in the past year.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Over the past 60 days, estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87, while estimates for 2026 have risen from $2.49 to $2.88 over the same period. Shares of CRMD have surged 54.7% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, the loss estimate for Castle Biosciences has narrowed from 64 cents to 34 cents for 2025. Over the same period, loss estimates for 2026 have improved from $1.82 to $1.06. CSTL stock has rallied 47.8% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 66.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
Key Takeaways
Mind Medicine (MindMed) (MNMD - Free Report) is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Two pivotal phase III studies — Voyage and Panorama — are currently enrolling MM120 ODT in GAD, a debilitating mental health condition where there is an urgent need for transformational innovation, with the last new drug approval occurring in 2007. Earlier data from the phase II study on MM120 ODT demonstrated efficacy that far exceeded the current standard of care and a favorable tolerability profile.
Top-line data from the Voyage study is anticipated in the first half of 2026, while that from Panorama is expected in the second half of 2026.
A phase III study called Emerge of MM120 ODT in MDD has enrolled faster than expected, with top-line data now expected in mid-2026, earlier than the prior expectation of the second half of 2026. The company plans to initiate Ascend, its second phase III study in MDD, in mid-2026.
MindMed’s rapid pipeline progress in 2025 led the stock to rise 101.2% in the past six months, outperforming the industry’s increase of 27.6%.
Image Source: Zacks Investment Research
MindMed’s second asset in the pipeline, MM402, is being developed for autism spectrum disorder. A phase II study is expected to be initiated by the end of 2025.
With three pivotal data readouts expected, 2026 could be transformational for MindMed. Its recent $258.9 million financing has further strengthened its balance sheet, which should allow it to accelerate the development of MM120.
Zacks Rank and Stocks to Consider
MindMed has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) . ANIP, CRMD and CSTL currently sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2025 adjusted EPS have increased from $7.29 to $7.56. Over the same period, EPS estimates for 2026 have surged from $7.81 to $8.08. Shares of ANIP have surged 52.1% in the past year.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Over the past 60 days, estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87, while estimates for 2026 have risen from $2.49 to $2.88 over the same period. Shares of CRMD have surged 54.7% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, the loss estimate for Castle Biosciences has narrowed from 64 cents to 34 cents for 2025. Over the same period, loss estimates for 2026 have improved from $1.82 to $1.06. CSTL stock has rallied 47.8% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 66.11%.